NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of 3D Systems Corporation (NYSE: DDD). Shareholders who purchased shares of DDD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/3d-systems-corporation-loss-submission-form/?id=157197&from=3 CLASS PERIOD: Aug ...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/capricor-loss-submission-form/?id=157205&from=3 CLASS PERIOD: October ...

LOS ANGELES, July 21, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 5, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired iRobot Corporation (“iRobot” or the “Company”) (NASDAQ: IRBT) securities between January 29, 2024 and March 11, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR IROBOT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO ...

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration and strong demand across all channels, attributed to distribution expansion and promotional activities [2]. Group 2: Sales Growth and Market Reaction - The sales growth during the relevant period may not be sustainable, as it could have been influenced by temporary trade inventory loading at key retailers [2]. - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply on hand, which would negatively impact growth in Q3 2025 [3]. - Following this announcement, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, indicating that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - A lawsuit has been filed against Reddit, Inc. and its senior executives for potential violations of federal securities laws, specifically related to misrepresentations about user growth impacted by Google's AI technology [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, titled Tamraz, Jr. v. Reddit, Inc., et al., No. 25-cv-05144 [2]. - Investors have until August 18, 2025, to request to be appointed to lead the case [2]. Group 2: Allegations Against Reddit - The complaint alleges that Reddit downplayed the negative impact of Google's AI on its user growth, which has been significant as users can find answers directly through Google without visiting Reddit [3][4]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Reddit securities [2]. Group 3: Stock Performance - Following a report on May 1, 2025, indicating a slowdown in daily active user growth, Reddit's stock price fell by $4.96, or over 4%, from $118.79 to $113.83 per share [5]. - On May 21, 2025, an analyst from Baird cut the stock price target due to concerns over Google's AI, leading to a further decline of $9.79, or over 9%, from $105.64 to $95.85 per share [6].

Core Viewpoint - RxSight, Inc. is under investigation for potential violations of federal securities laws following a significant decline in its stock price due to revenue forecast cuts related to a slowdown in product utilization [1][4][5]. Company Overview - RxSight specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [2]. Financial Performance - The company previously reported strong sales for its LAL and Light Delivery Device (LDD), but began experiencing a slowdown in LAL utilization noted in 2024 [3]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 per share [4]. - A further revenue forecast cut occurred on July 8, 2025, attributed to slower LAL utilization, resulting in another 38% decline in stock price from $12.79 to $7.95 per share [5].

Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of Centene Corporation securities between December 12, 2024, and June 30, 2025, alleging misleading statements regarding the company's financial performance and enrollment rates [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that during the Class Period, Centene's management provided investors with overly positive information regarding expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year [5]. - Defendants allegedly made confident statements about Centene's enrollment and morbidity rates, as well as strong retention rates in its Medicare business, while concealing material adverse facts about the true state of these metrics [5]. Group 2: Participation Information - Investors who purchased Centene common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

SAN DIEGO, July 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Neogen Corporation (NASDAQ: NEOG) securities between January 6, 2023 and June 3, 2025. Neogen is a food safety company that manufactures and markets products and services dedicated to food and animal safety.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Inve ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Jasper Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On July 7, 2025, Jasper Therapeutics released updated data from its BEACON Phase 1b/2a study of briquilimab, indicating issues with a specific drug product lot that affected results in certain patient cohorts [3] - The stock price of Jasper Therapeutics fell by $3.73 per share, or 55.1%, closing at $3.04 per share following the announcement of the study results [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]